PRN: 'The Global Advanced Wound Care Market to be Worth $14.6bn by 2021' Says Latest visiongain Report

15/nov/2011 12.02.14 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

'The Global Advanced Wound Care Market to be Worth $14.6bn by 2021' Says Latest visiongain Report

 
[15-November-2011]
 

LONDON, November 15, 2011 /PRNewswire/ --

http://www.visiongain.com/Report/716/Advanced-Wound-Care-World-Market-Prospects-2011-2021

A new report by visiongain, a London-based business information provider predicts the global advanced wound care market to be worth $14.6bn by 2021. The market generated $6.2bn in 2010, according to Advanced Wound Care: World Market Prospects 2011-2021, published in November 2011.

Advanced wound care is now the physician's choice for the treatment of both acute and chronic wounds, commonly used in the treatment of burns, diabetic ulcers and pressure ulcers. The advanced wound care market has a significant opportunity to expand, owing to the increasing prevalence of diabetes and obesity leading to an increase in chronic wounds, in both developed and emerging economies. Emerging economies are beginning to transition from the traditional wound care to advanced wound care, as the products in the latter segment become more affordable and the healthcare coverage expands.

James Sheppard, healthcare industry analyst says 'The advanced wound care market has enjoyed strong growth over recent years, driven by novel devices such as negative pressure wound therapy (NPWT or VAC). Growth will be driven by biologics and novel devices. Over the course of the next decade, demand for advanced wound care will increase due to an increasing prevalence of chronic wounds as diabetes and obesity rates increase.'

Visiongain's research suggests that the advanced wound care market will benefit from the growth of emerging economies. Countries including China and India are already witnessing an increase in lifestyle related disorders such as diabetes and obesity, with increasing spending power. In the near future, mature markets such as the US and EU will drive the adoption of novel wound care devices and biologics, which command high prices in the market. Wound care biologics are still to achieve the attention they deserve, since the high cost of treatment has prevented their wide scale use. However, the market for wound care biologics will witness strong growth as their cost-effectiveness becomes evident.

Visiongain's analysis of the moist wound care, wound care devices and wound care biologics pipelines shows a number of innovative products with a great deal of promise. The current market leaders will continue to see strong growth in the early part of the decade. This new report adds to visiongain's wide range of analytical reports in healthcare and other industry areas.

Table of Contents
1. Executive Summary
1.1 Advanced Wound Care: Market Review
1.2 Overview of Chapter Content
1.3 Research and Analysis Method
1.4 Glossary of Terms Relating to Advanced Wound Care

2. Introduction
2.1 What is a Wound?
2.1.1 Wound Classification
2.1.1.1 Acute Wounds
2.1.1.2 Chronic Wounds
2.1.1.2.1 The Increasing Prevalence of Chronic Wounds
2.1.1.3 Burns
2.2 The Skin
2.2.1 The Phases of Wound Healing
2.2.1.1 The Inflammatory Phase
2.2.1.2 The Proliferation Phase
2.2.1.3 The Fibroblastic Phase
2.2.1.4 The Maturation Phase
2.3 Wound Care
2.3.1 The Functions of Wound Care
2.3.2 The History of Wound Care
2.4 Wound Care Categories
2.4.1 Traditional Wound Care
2.4.2 Advanced Wound Care (AWC)
2.4.2.1 Moist Wound Care (MWC)
2.4.2.1.1 Alginate Dressings
2.4.2.1.2 Foam Dressings
2.4.2.1.3 Hydrocolloid Dressings
2.4.2.1.4 Hydrogel Dressings
2.4.2.2 Wound Care Devices
2.4.2.2.1 Negative Pressure Wound Therapy (NPWT)
2.4.2.2.2 Ultrasound for Wound Therapy
2.4.2.2.3 Electrical Stimulation
2.4.2.3 Biologics
2.4.2.3.1 Skin Replacement Therapies
2.4.2.3.2 Collagen Based Therapies
2.4.2.3.3 Cell Therapies
2.5 Regulation of Advanced Wound Care
2.5.1 The US Approval and Regulation System
2.5.2 The European Approval and Regulation Process

3. The Global Advanced Wound Care Market, 2010-2021
3.1 Advanced Wound Care: Market Overview
3.1.1 The Size of the Advanced Wound Care Market in 2010
3.2 Regional Market Breakdown, 2010
3.2.1 The US, European and Japanese Markets, 2010
3.2.2 The Chinese and Indian Market, 2010
3.3 Global Advanced Wound Care Market Forecast, 2011-2015
3.4 Global Advanced Wound Care Market Forecast, 2015-2021
3.5 Leading National Markets for Advanced Wound Care: Sales Forecasts, 2011-2021
3.5.1 The US, European and Japanese Markets, 2011-2021
3.5.1.1 The US Market
3.5.1.2 The European Market
3.5.1.3 The Japanese Market
3.5.2 The Chinese and Indian Markets, 2011-2021
3.5.2.1 The Chinese Market
3.5.2.2 The Indian Market

4. The Moist Wound Care Market, 2010-2021
4.1 The Moist Wound Care Market: Overview
4.1.1 The Moist Wound Care Market, 2010
4.1.2 Moist Wound Care Market Forecast, 2011-2021
4.2 The Moist Wound Care Market Segments, 2011-2021
4.2.1 The Hydrocolloid Dressings Market
4.2.2 The Foam Dressings Market
4.2.3 The Alginate Dressings Market
4.2.4 The Hydrogel Dressings Market
4.2.5 Other MWC Dressings Market
4.2.5.1 Hydrofiber Technology (ConvaTec)
4.3 The Moist Wound Care Pipeline
4.3.1 NanoDOX (Nanotherapeutics)
4.3.2 Novel Antimicrobial Silver Dressing (AGT Sciences Ltd)
4.3.3 '1' Primary Wound Dressing (Phytoceuticals)
4.4 SWOT Analysis of the Moist Wound Care Market, 2011-2021
4.4.1 Strengths
4.4.1.1 Established Segment of the Market
4.4.1.2 Wide Variety of Products
4.4.1.3 More Effective than Traditional Wound Care
4.4.2 Weaknesses
4.4.2.1 Less Effective than Some Devices and Biologics
4.4.2.2 Weak R&D Pipeline
4.4.3 Opportunities
4.4.3.1 Increasing Prevalence of Chronic Wounds
4.4.3.2 Cheap Alternative to Devices and Biologics
4.4.4 Threats
4.4.4.1 Emerging Technologies May be More Effective
4.4.4.2 Lack of R&D Spending Will Stifle Innovation

5. Wound Care Devices Market, 2010-2021
5.1 Wound Care Devices Market: Overview
5.1.1 The Wound Care Devices Market in 2010: Segment and Regional Breakdown
5.1.2 The Wound Care Devices Forecast, 2011-2021
5.2 The NPWT Market
5.2.1 The NPWT Market in 2010
5.2.2 Leading NPWT Devices: Product Analysis
5.2.2.1 V.A.C. Therapy (KCI)
5.2.2.1.1 V.A.C. Via (Kinetic Concepts Inc)
5.2.2.2 RENASYS Systems (Smith & Nephew)
5.2.2.3 Other NPWT Systems
5.2.2.3.1 POSiFECT (Biofisica)
5.3 The NPWT Market Forecast, 2011-2015
5.4 The NPWT Market Forecast, 2015-2021
5.5 The Wound Care Devices Pipeline
5.5.1 dermaPACE (Sanuwave Health)
5.5.2 O-ACE-Sys (Ingenious Technologies Corporation)
5.5.3 Red Light Wave Therapy (Lightwave Technologies)
5.5.4 MIST Therapy (Celleration)
5.6 SWOT Analysis of the Wound Care Devices Market, 2011-2021
5.6.1 Strengths
5.6.1.1 More Effective than Other Forms of Wound Care
5.6.1.2 Constant Innovation in the Market
5.6.2 Weaknesses
5.6.2.1 Dominated by Few Large Companies
5.6.2.2 NPWT Dominates the Market
5.6.3 Opportunities
5.6.3.1 Low Cost NPWT Systems will Drive Growth
5.6.3.2 Increasing Prevalence of Chronic Wounds
5.6.4 Threats
5.6.4.1 Controversy Regarding Safety of NPWT
5.6.4.2 Ongoing Legal Battles Threaten Innovation

6. The Wound Care Biologics Market, 2010-2021
6.1 Wound Care Biologics Market: Overview
6.1.1 Wound Care Biologics Market in 2010: Market Segments and Regional Breakdown
6.1.2 The Wound Care Biologics Market Forecast, 2011-2021
6.2 The Skin Replacement Market
6.2.1 The Skin Replacement Market in 2010
6.2.2 Leading Products in the Skin Replacement Market, 2010
6.2.2.1 Dermagraft (Advanced BioHealing, a Division of Shire Pharmaceuticals)
6.2.2.2 Apligraf (Organogenesis)
6.2.2.3 Other Leading Products
6.2.3 The Skin Replacement Market Forecast, 2011-2015
6.2.4 The Skin Replacement Market Forecast, 2015-2021
6.3 Collagen Based Therapy
6.3.1 Collagen Based Therapy Market in 2010
6.3.2 The Collagen Based Therapy Market Forecast, 2011-2015
6.3.3 The Collagen Based Therapy Market Forecast, 2015-2021
6.4 The Cell Therapy Market
6.4.1 The Cell Therapy Market in 2010
6.4.2 Leading Products in the Cell Therapy Market, 2010
6.4.3 The Cell Therapy Market Forecast, 2011-2015
6.4.4 The Cell Therapy Market Forecast, 2015-2021
6.5 The Biologics Pipeline
6.5.1 Stem Cells
6.5.1.1 Stem Cell Skin Gun (McGowan Institute for Regenerative Medicine at the University of Pittsburgh)
6.5.1.2 Adult Stem Cells (Cryo-Cell International and The Snyder Wound Research Institute)
6.5.1.3 Mesenchymal Stem Cells (Nara University, Japan)
6.5.2 Artificial Skin
6.5.2.1 e-Skin (UC Berkeley)
6.5.2.2 Genetically Modified Artificial Skin (University of Cincinnati)
6.5.3 Cell Therapy
6.5.3.1 ReCell (Avita Medical)
6.5.4 Automated Artificial Skin Production
6.5.4.1 The Tissue Factory (Fraunhofer Institute)
6.5.5 Nanotechnology
6.5.5.1 DermaFuse (Missouri S&T and Mo-Sci Corporation)
6.5.5.2 Phytochemical Tissue Bonding (Harvard University Institute of Photomedicine)
6.5.5.3 Giant Unilamellar Vesicles (University of Bath)
6.5.6 Collagen Based Therapy
6.5.6.1 Artificial Collagen Based Wound Care (Cornell University)
6.5.7 Diagnostic Tests
6.5.7.1 WOUNDCHEK (Systagenix Wound Management)
6.6 SWOT Analysis of the Wound Care Biologics Market, 2011-2021
6.6.1 Strengths
6.6.1.1 More Effective Than Other Forms of Wound Care
6.6.1.2 New Technology with Constant Innovation
6.6.1.3 Strong R&D Pipeline
6.6.2 Weaknesses
6.6.2.1 Small Start-up Companies Dominate the Market
6.6.2.2 Expensive Technology
6.6.2.3 High Barriers to Entry
6.6.3 Opportunities
6.6.3.1 Strong Innovation Will Drive Growth
6.6.3.2 Stem Cells Offer Multiple Opportunities
6.6.3.3 Increasing Prevalence of Chronic Wounds
6.6.4 Threats
6.6.4.1 Controversy Regarding the Effectiveness of Some Biologics
6.6.4.2 High Barriers to Entry will Deter Competitors
6.6.4.3 Competition from MWC and Devices

7. Advanced Wound Care Market: Analysis by Company, 2010
7.1 Smith & Nephew (S&N)
7.1.1 Smith & Nephew Advanced Wound Care Sales, 2010
7.1.2 Smith & Nephew Pipeline
7.2 Kinetic Concepts Inc (KCI)
7.2.1 KCI Advanced Wound Care Sales, 2010
7.2.2 KCI Pipeline
7.2.3 The Sale of KCI
7.3 ConvaTec
7.3.1 ConvaTec Sales, 2010
7.3.2 ConvaTec Advanced Wound Care Sales, 2010
7.3.3 ConvaTec Pipeline
7.4 Coloplast
7.4.1 Coloplast Sales, 2010
7.4.2 Coloplast Advanced Wound Care Sales, 2009/2010
7.5 Systagenix Wound Management
7.5.1 Systagenix Pipeline

8. Expert Opinions
8.1 Dr Edward Lin, CEO & Founder of Ingenious Technologies Corporation
8.1.1 The Wound Care Market
8.1.2 O-ACE-Sys Device Being Developed by Dr Lin
8.1.3 NPWT Devices
8.1.4 The Future of Wound Care Devices
8.2 Professor Kiminobu Sugaya, Professor of Neuroscience, Burnett School of Biomedical Science, University of Central Florida
8.2.1 The Current Stem Cell Field
8.2.2 Public Perception of Stem Cell Research
8.2.3 iPS cells and Wound Healing

9. Conclusions
9.1 The Advanced Wound Care Market, 2010-2021
9.1.1 Growth will be Driven by an Increasing Prevalence of Chronic Wounds
9.1.2 Emerging Markets will Drive Growth
9.2 The Moist Wound Care Market
9.3 The Wound Care Devices Market
9.4 The Wound Care Biologics Market

Appendix A
Appendix B - Visiongain report evaluation form

Companies Listed
3M
ACell
Advanced BioHealing
Advanced Medical Solutions Group
AGT Sciences Ltd
Apax Partners
Avista Capital partners
Avita Medical
Biofisica
Biolight AB
Blackstone Group
BlueSky Medical
Boehringer Wound Systems LLC
Brennen Medical
Bristol-Myers Squibb
Celleration
Center for Biologics Evaluation and Research
Centres for Medicare & Medicaid Services (CMS)
ConvaTec
Cornell University
Covidien
Cryo-Cell International
Derma Sciences
Dr. Suwelack Skin & Health Care
E.R Squibb & Sons
Fidia
Genadyne Biotechnologies
Genzyme
Genzyme Biosurgery
Food & Drug Administration (FDA)
Forticell Bioscience
Harvard University Institute of Photomedicine
HealO Medical
HealthPoint
Ingenious Technologies Corporation
Innovative Therapies Inc
Integra Life Sciences
Japanese Ministry of Health, Labour and Welfare (MHLW)
Johnson & Johnson
Kalypto Medical
Kinetic Concepts Inc (KCI)
Lescarden
LifeCell
Lightwave Technologies
MacroCure
Massachusetts Institute of Technology (MIT)
McGowan Institute for Regenerative Medicine at the University of Pittsburgh
MCS Med
Medela Inc
Medestea Internazionale
Medline Industries
Missouri S&T
Mo-Sci Corporation
Molnlycke
Nanotherapeutics
Nara University, Japan
Nordic Capital Partners
Novartis
Office of Combination Products
Ogenix Corporation
One Equity Partners
Ortec International
Osiris Therapeutics
Pfizer
Phytoceuticals
Polyheal
Progenicyte
Prospera
Sanuwave Health Inc
Smith & Nephew
Snyder Wound Research Institute
Spiracur
Systagenix
Talley Group
The Fraunhofer Institute for Interfacial Engineering and Biotechnology
UC Berkeley
UDL Laboratories
UK Healthcare Industry Task Force
University Hospital Bern, Switzerland
University of Bath
University of Chicago
University of Cincinnati
US Armed Forces Institute of Regenerative Medicine
Wound Management Technologies
Wright Medical

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Pharmaceutical, Telecoms, Energy, Defence and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. 

For further information about this report please click on http://www.visiongain.com/Report/629/In-Vitro-Diagnostics-World-Market-Outlook-2011-2021  

Contact: Sara Peerun
Tel: +44(0)207-336-6100
Email: sara.peerun@visiongainglobal.com
Web: http://www.visiongain.com

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl